How Washington Is Repricing Healthcare, Medicare Advantage Headwinds & AI
We speak with Hedgeye’s Emily Evans about how healthcare policy is increasingly driving market outcomes, arguing Wall Street is underestimating policy’s impact. They discuss Medicaid work requirements as a renewed eligibility philosophy that may also reduce fraud, waste, and abuse, with managed Medicaid insurers (e.g., Centene, Molina, UnitedHealth, Elevance) most exposed to enrollment declines. Evans explains how the IRA redesign of Medicare Part D shifts risk away from federal reinsurance, likely raising standalone Part D premiums after the 2023 premium subsidy/risk corridor ends, potentially worsening adverse selection and pushing beneficiaries toward Medicare Advantage amid rural provider tensions. They cover AI’s near-term use in administrative battles and productivity within hospitals, skepticism about “AI cures cancer” hype, and a bearish view on hospitals and Medicare Advantage, bullishness on big pharma and GLP-1s (including direct-to-consumer channels), bearishness on biotech, and the market implications of expanding price transparency, including the Patients Deserve Price Tags Act. 00:00 Welcome and Setup 00:14 Policy Drives Markets 01:50 Meet Emily Evans 03:28 What Markets Misprice 06:01 Wall Street Policy Blindspots 10:03 Medicaid Work Requirements 18:20 Who Bears Medicaid Risk 20:13 Part D Risk Shift 23:47 Premiums and Adverse Selection 27:30 AI and EHR Power 29:03 AI Capital Cycle 35:51 Lightning Round Outlook 43:58 Price Transparency Shock 48:58 Wrap Up and Disclaimer